BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

940 related articles for article (PubMed ID: 21278435)

  • 1. Triple-negative breast cancer: an unmet medical need.
    Hudis CA; Gianni L
    Oncologist; 2011; 16 Suppl 1():1-11. PubMed ID: 21278435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Directed therapy of subtypes of triple-negative breast cancer.
    Carey LA
    Oncologist; 2011; 16 Suppl 1():71-8. PubMed ID: 21278443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
    Cheang MC; Voduc D; Bajdik C; Leung S; McKinney S; Chia SK; Perou CM; Nielsen TO
    Clin Cancer Res; 2008 Mar; 14(5):1368-76. PubMed ID: 18316557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Directed therapy of subtypes of triple-negative breast cancer.
    Carey LA
    Oncologist; 2010; 15 Suppl 5():49-56. PubMed ID: 21138955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding and treating triple-negative breast cancer.
    Anders C; Carey LA
    Oncology (Williston Park); 2008 Oct; 22(11):1233-9; discussion 1239-40, 1243. PubMed ID: 18980022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential prognostic tumor biomarkers in triple-negative breast carcinoma.
    Peng Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):666-72. PubMed ID: 23073572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
    Kurebayashi J
    Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy for triple-negative breast cancer: where are we?
    Duffy MJ; McGowan PM; Crown J
    Int J Cancer; 2012 Dec; 131(11):2471-7. PubMed ID: 22581656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular stratification of triple-negative breast cancers.
    Perou CM
    Oncologist; 2011; 16 Suppl 1():61-70. PubMed ID: 21278442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic triple-negative breast cancer.
    Rakha EA; Chan S
    Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):587-600. PubMed ID: 21524569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of triple-negative breast cancer.
    de Ruijter TC; Veeck J; de Hoon JP; van Engeland M; Tjan-Heijnen VC
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):183-92. PubMed ID: 21069385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecularly targeted therapies for metastatic triple-negative breast cancer.
    Bayraktar S; Glück S
    Breast Cancer Res Treat; 2013 Feb; 138(1):21-35. PubMed ID: 23358903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current treatment options in triple negative breast cancer.
    Rodler E; Korde L; Gralow J
    Breast Dis; 2010; 32(1-2):99-122. PubMed ID: 21778572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
    Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
    Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is triple-negative breast cancer?
    Irvin WJ; Carey LA
    Eur J Cancer; 2008 Dec; 44(18):2799-805. PubMed ID: 19008097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple negative breast cancer: from molecular portrait to therapeutic intervention.
    Carotenuto P; Roma C; Rachiglio AM; Botti G; D'Alessio A; Normanno N
    Crit Rev Eukaryot Gene Expr; 2010; 20(1):17-34. PubMed ID: 20528735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer.
    Perez EA; Patel T; Moreno-Aspitia A
    Breast Cancer Res Treat; 2010 Jun; 121(2):261-71. PubMed ID: 20229176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.
    Venkitaraman R
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.